Skip to main content
. Author manuscript; available in PMC: 2013 Jul 15.
Published in final edited form as: Neuropharmacology. 2011 Aug 23;62(3):1442–1452. doi: 10.1016/j.neuropharm.2011.08.026

Figure 8.

Figure 8

One month of asenapine treatment attenuates PCP-induced decrease in 5HT turnover in orbital frontal cortex. Abbreviations and treatment codes, as in Figure 3. *Significant decrease compared with Sal-Sal, † significant increase compared with PCP-Sal (n=8 per group).